Open AccessINNOVATIONS TO TOPICAL THERAPY OF ROSACEA
Author(s) -
O. Yu Olisova,
Олисова О. Ю,
Н Г Кочергин,
Кочергин Н. Г,
Е. А. Смирнова,
Смирнова Елена Анатольевна
Publication year - 2017
Publication title -
rossijskij žurnal kožnyh i veneričeskih boleznej
Language(s) - English
Resource type - Journals
eISSN - 2412-9097
pISSN - 1560-9588
DOI - 10.18821/1560-9588-2017-20-5-270-274
Subject(s) - rosacea , medicine , dermatology , tolerability , etiology , disease , brimonidine , ivermectin , placebo , adverse effect , surgery , alternative medicine , pathology , intraocular pressure , acne , veterinary medicine
The main pathogenetic aspects of rosacea, various classifications of dermatosis and the modern clinical classification are presented. The symptoms that differentiate rosacea from other dermatoses are described. Contradictory of modern scientific concepts of different researchers, approaches to etiology, pathogenesis and treatment has been noted. The social significance of rosacea, the importance and possibility of eliminating the symptoms of the disease at early stages, the achievement and prolongation of remission are shown. The main triggers for the manifestation of rosacea, which should be taken into account to achieve the maximum effect in the treatment of the disease, are indicated. The domestic and foreign clinical recommendations on the treatment of the disease are considered in view of the appearance of new external drugs. The results of several studies in the USA and Canada on the efficacy of 1% ivermectin cream and 0.5% brimonidine tartrate gel compared to placebo are shown. The first domestic positive experience of self-study with 1% ivermectin cream (Solantra®) and 0.5% brimonidine tartrate gel (Mirvazo Derm®) is presented. The high efficacy and very good tolerability of this drugs, as well as the absence of any side effects in patients with moderate to severe rosacea are shown.